Drug interaction study explores cediranib and rifampicin in advanced cancer
NCT ID NCT00750841
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This early-phase study looks at how a common antibiotic, rifampicin, changes the way the body processes the experimental cancer drug cediranib. About 64 adults with advanced solid tumors that no longer respond to standard treatments will take both drugs. The goal is to understand the drug interaction, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Dundee, DD1 9SY, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE1 9RT, United Kingdom
Conditions
Explore the condition pages connected to this study.